Significant Ownership of L.P. ACORN BIOVENTURES

Signature - Title
Anders Hove - Manager of General Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by L.P. ACORN BIOVENTURES.

Notify me when L.P. ACORN BIOVENTURES files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of L.P. ACORN BIOVENTURES

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
OKUR OnKure Therapeutics, Inc. Common stock, par value $0.0001 per share 22% $7,099,185 2,839,674 Anders Hove 15 May 2025
BCAB BioAtla, Inc. Common Stock, $0.0001 par value per share 8.3% $2,127,449 4,835,111 Anders Hove 15 May 2025
PBYI PUMA BIOTECHNOLOGY, INC. Common Stock, $0.0001 par value per share 8% $11,859,557 +$1,988,442 3,940,052 +20% Anders Hove 31 Dec 2024
MURA Mural Oncology plc Common Stock, $0.01 par value per share 7.6% $3,369,527 +$547,205 1,286,079 +19% Anders Hove 31 Dec 2024
YMAB Y-mAbs Therapeutics, Inc. Common stock, par value $0.0001 per share 6.2% $13,338,337 -$1,431,000 2,796,297 -9.7% Anders Hove 19 Aug 2025
ATHA Athira Pharma, Inc. Common Stock, $0.0001 Par Value 6.2% $1,345,504 +$212,929 596,068 +19% Anders Hove 06 Jan 2026
JSPR Jasper Therapeutics, Inc. Common Stock, $0.001 Par Value 5.3% $2,660,821 -$537,000 1,486,492 -17% Anders Hove 23 Jan 2026
CADL Candel Therapeutics, Inc. Common stock, par value $0.0001 per share 5.2% $14,115,428 2,580,517 Anders Hove 25 Jun 2025

Schedules 13D/G Reported by L.P. ACORN BIOVENTURES:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.